Johannes Zuber
The genetic complexity, heterogeneity and plasticity of human cancers pose daunting challenges for the development of effective targeted therapies. New functional genetic tools such as CRISPR/Cas9, RNAi and targeted protein degradation have fundamentally changed the way we can approach this problem. Our lab develops and employs these tools to systematically identify and mechanistically study key regulators and dependencies in genetically engineered cancer models and tumor-associated immune cells.